ICCOV
Alternative Names: COVID-2019 DNA vaccine - Immuno Cure 3/University of Hong Kong; IMC-002 - Immuno Cure; SARS-CoV-2 DNA Vaccine - Immuno Cure 3/University of Hong KongLatest Information Update: 15 Dec 2021
At a glance
- Originator University of Hong Kong
- Developer Immuno Cure; University of Hong Kong
- Class COVID-19 vaccines; DNA vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 01 Nov 2021 Preclinical trials in COVID-2019 infections (Prevention) in China (IM)
- 01 Nov 2021 University of Hong Kong and Immuno Cure 3 Limited plans a phase I trial in COVID-2019 infections (Prevention) in November 2021 (IM, Injection) (NCT05102643)